Picture of Puretech Health logo

PRTC Puretech Health Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareAdventurousMid CapSucker Stock

Momentum

Relative Strength (%)
1m+12.85%
3m+3.91%
6m-31.09%
1yr-44.77%
Volume Change (%)
10d/3m-17.23%
Price vs... (%)
52w High-53.83%
50d MA+8.14%
200d MA-22.02%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-20.88%
Return on Equity-9.59%
Operating Margin-864.29%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Puretech Health EPS forecast chart

Profile Summary

PureTech Health PLC is a clinical stage biotherapeutics company. The Company is engaged in discovering, developing and commercializing medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases, and neurological and neuropsychological disorders, among others. The Company’s pipeline is comprised of 27 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization. The Company’s wholly owned pipeline consists of six therapeutic candidates including LYT-100, LYT-200, LYT-210, LYT-300, LYT-500, LYT-510, and LYT-503/IMB-150. Its segments include Internal, Controlled Founded Entity, Non-Controlled Founded Entities, and Parent Company and Other. The Internal segment is advancing wholly owned programs which is focused on immunological, fibrotic and lymphatic system disorders.

Directors

Last Annual
December 31st, 2021
Last Interim
December 31st, 2021
Incorporated
May 8th, 2015
Public Since
June 19th, 2015
No. of Employees
95
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
gb flag iconLondon Stock Exchange
Shares in Issue
285,047,455

PRTC Share Price Performance

Similar to PRTC

Picture of 4Basebio logo

4Basebio

gb flag iconLondon Stock Exchange

Picture of 4d Pharma logo

4d Pharma

gb flag iconLondon Stock Exchange

Picture of Allergy Therapeutics logo

Allergy Therapeutics

gb flag iconLondon Stock Exchange

Picture of Arecor Therapeutics logo

Arecor Therapeutics

gb flag iconLondon Stock Exchange

Picture of Avacta logo

Avacta

gb flag iconLondon Stock Exchange

FAQ

Or unlock with your email

Or unlock with your email